Grade C · preclinical3 peptides · 52 studies
Glow Stack
No summary filed yet — the Librarian is still assembling this protocol.
This is a description, not a protocol to follow
Everything below is a summary of what people report doing and what the literature contains. Nothing here is medical advice.
What the evidence actually supports
Supported in animals
Animal-model studies indexed · 13
Cell and in-vitro studies indexed · 9
Reviews and uncategorised studies · 22
Not established
Any effect in humans · 8 human studies indexed
Any benefit from combining them · no combination study in our index
Human dose, route or duration · no PK study indexed
Protocol details
The Glow Stack protocol involves the peptides BPC-157, GHK-Cu, and TB-500. However, published studies have not investigated this specific combination of peptides together. Instead, the available research focuses on each compound individually, providing insights into their potential applications and effects.
GHK-Cu has been studied in various contexts, including its use in a novel wound dressing that achieved 99.8% closure in a mouse model of antibiotic-resistant infection [2]. Despite this promising result, the applicability of GHK-Cu to human wounds remains unestablished. Other studies have highlighted its potential as a therapeutic cargo and its regenerative properties, but they emphasize the need for more rigorous clinical trials to validate these findings [11], [14].
BPC-157 has shown some preclinical promise, particularly in rodent models for ischemia-reperfusion injury [12]. However, human evidence is limited, with systematic reviews indicating that while there may be anecdotal symptom improvement, the overall evidence is weak and insufficient for clinical use outside of regulated trials [10], [8]. Case reports involving BPC-157 have not provided definitive conclusions regarding its efficacy [3], [4], [5], [6], [7].
TB-500, or Thymosin Beta-4 Fragment, has been discussed in the context of orthopaedic practice, where it is noted that clinicians should exercise caution due to a lack of validated human efficacy and safety data [9]. The evidence surrounding TB-500 is primarily observational and does not support its routine clinical recommendation.
In summary, while individual studies on BPC-157, GHK-Cu, and TB-500 exist, there is no research that has specifically tested the Glow Stack protocol as a combination of these peptides. Further investigation is needed to explore the potential interactions and collective effects of these compounds.
Sources
[2] Asymmetric-interfacial nanofibrous membranes with diode-like exudate transport for nanozyme-catalyzed antibacterial wound healing. — Biomaterials, 2026 https://doi.org/10.1016/j.biomaterials.2026.124483
[3] First Case Report of Triple Recurrent Cholangitis of "Coildocholithiasis," Following Hepatic Artery Pseudoaneurysm Embolization. — DEN open, 2023 https://doi.org/10.1002/deo2.70407
[4] Mechanism of Fibrotic Anastomosis Formation in Endoscopic Ultrasound-guided Hepaticogastrostomy Using a Plastic Stent: Insights From an Autopsy Case of Perihilar Cholangiocarcinoma. — DEN open, 2023 https://doi.org/10.1002/deo2.70350
[5] Endoscopic Diagnosis of Necator americanus Infection Presenting With Persistent Iron-Deficiency Anemia: Usefulness of Image-Enhanced Endoscopy and Capsule Endoscopy. — DEN open, 2023 https://doi.org/10.1002/deo2.70352
[6] Time to Confirmed Completion of Bowel Preparation as a Preprocedural Indicator of Colonoscope Insertion Difficulty: A Prospective Observational Study. — DEN open, 2023 https://doi.org/10.1002/deo2.70375
[7] Gastric Metastasis of Uterine Leiomyosarcoma Detected During Surveillance Endoscopy and Resected by Endoscopic Submucosal Dissection After Multiple Metachronous Metastases: A Case Report. — DEN open, 2023 https://doi.org/10.1002/deo2.70370
[8] Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. — The Journal of the American Academy of Orthopaedic Surgeons, 2023 https://doi.org/10.5435/jaaos-d-26-00049
[9] Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. — The Journal of the American Academy of Orthopaedic Surgeons, 2026 https://pubmed.ncbi.nlm.nih.gov/42937313/
[10] Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. — Acta orthopaedica Belgica, 2023 https://doi.org/10.52628/92.3.15837
[11] GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. — Pharmaceutics, 2026 https://doi.org/10.3390/pharmaceutics18091077
[12] BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. — International journal of molecular sciences, 2020 https://doi.org/10.3390/ijms27188344
[14] The Regenerative Potential of GHK-Cu in Aesthetic Medicine. — Aesthetic surgery journal, 2026 https://doi.org/10.1093/asj/sjag169
Research & studies for this protocol
52 rows · showing 24Newest first
| Study | Compound | Source | Year |
|---|---|---|---|
| This narrative review evaluated the evidence, safety, and patient counseling regarding BPC-157 and other investigational peptides in orthopaedic practice. The review highlighted that BPC-157 has the largest body of direct musculoskeletal preclinical evidence, primarily from small-animal studies. However, human evidence is limited to one small retrospective uncontrolled case series. | BPC-157 | europepmc | 2023 |
| This narrative review evaluated the molecular rationale, safety, and efficacy of TB-500 in the context of orthopaedic practice. The review highlights the limited clinical validation of TB-500 and its distinction from full-length thymosin beta-4. No FDA-approved indications or controlled human efficacy evidence for TB-500 in musculoskeletal applications were reported. | TB-500 (Thymosin Beta-4 Fragment) | PubMed | 2026 |
| This systematic review evaluated the efficacy and safety of BPC-157 for orthopaedic and regenerative purposes in humans. Three studies with a total of 30 participants were included, reporting symptom improvement without treatment-related adverse events. However, the studies were of poor methodological quality. | BPC-157 | europepmc | 2023 |
| GHK-Cu and its effects on matrix remodeling, inflammation, and tissue repair were evaluated. The study conducted a systematic review of existing literature and clinical evidence. Findings indicate that while preclinical data support certain effects, clinical evidence remains sparse and lacks quality standards. | GHK-Cu | europepmc | 2026 |
| This critical review evaluates the preclinical evidence for BPC 157 in rodent ischemia-reperfusion injury (IRI) models, focusing on various biological responses. The review highlights the association of BPC 157 with oxidative injury attenuation and modulation of vascular responses. However, it emphasizes that the evidence is heterogeneous and preliminary. | BPC-157 | europepmc | 2020 |
| This systematic review evaluates the mechanisms and applications of GHK-Cu in topical microneedle delivery. The review synthesizes literature from 2005 to 2026, highlighting the lack of adequately powered human trials. It emphasizes the need for further clinical studies to validate preclinical findings. | GHK-Cu | PubMed | 2026 |
| Not reported in abstract. | GHK-Cu | PubMed | 1980 |
| Not reported in abstract. | GHK-Cu | PubMed | 1996 |
| This systematic review evaluates the efficacy, safety, and regenerative mechanisms of GHK-Cu in aesthetic medicine. It included 20 studies, with 18 being preclinical and 2 randomized controlled trials (RCTs). The review found that GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls. | GHK-Cu | europepmc | 2026 |
| Not reported in abstract. | TB-500 (Thymosin Beta-4 Fragment) | PubMed | 2011 |
| Not reported in abstract. | TB-500 (Thymosin Beta-4 Fragment) | PubMed | 2012 |
| This review addresses the design challenges of bioabsorbable flow diverters (FDs) for intracranial aneurysm management. It examines how bioactive materials can balance scaffold resorption with aneurysm occlusion. The paper emphasizes the importance of material properties and design principles in enhancing device functionality. | GHK-Cu | europepmc | 2026 |
| This study investigates the tri-specific antibody JMB2403, designed to activate IL2Rβγ and block PD-1, in various models. The antibody was tested in engineered Jurkat cells and xenograft models for anti-tumor efficacy and immune cell activation. The results indicated a dose-dependent increase in CD8+ T cell proliferation without IL-2-related toxicities. | TB-500 (Thymosin Beta-4 Fragment) | europepmc | 2026 |
| This study developed a biomimetic nanoplatform targeting Alzheimer's disease, integrating multiple therapeutic bioactivities. In APP/PS1 transgenic mice, treatment resulted in reduced Aβ plaque deposition and improved cognitive functions. The study reports various in vitro and in vivo effects without making therapeutic claims. | GHK-Cu | europepmc | 2026 |
| This study measured the effects of systemic administration of tetrathiomolybdate (TTM) on collagen deposition and secretory function in irradiated mouse salivary glands. Mice received TTM in drinking water at a concentration of 0.1 mg/mL starting 7 days before and continuing through 7 days after a single 15-Gy dose of radiation therapy. The results indicated that TTM treatment improved stimulated saliva flow compared to control. | GHK-Cu | europepmc | 2026 |
| This study investigates asymmetric-interfacial Janus nanofibrous membranes for antibacterial wound healing in a murine model. The dressing achieved 99.8% wound closure by day 12 in infected wounds. The study highlights the membrane's ability to reduce bacterial burden and enhance healing without specific therapeutic claims. | GHK-Cu | europepmc | 2026 |
| A 72-year-old man experienced three episodes of cholangitis due to coil migration following treatment for a hepatic artery pseudoaneurysm. The patient underwent transcatheter arterial embolization with tornado microcoils. This case highlights the complications associated with coil migration into the bile duct. | BPC-157 | europepmc | 2023 |
| This study investigates the role of OTUD5 in acute myeloid leukemia (AML) progression by regulating SLC7A11 to suppress ferroptosis. OTUD5 was analyzed in AML patient samples and cell lines, with functional assays conducted following OTUD5 silencing and overexpression. The findings suggest that OTUD5 enhances SLC7A11 stability, promoting AML cell survival. | TB-500 (Thymosin Beta-4 Fragment) | europepmc | 2026 |
| This study investigates the properties of a single layer of Bi2Sr2CuO6+δ (Bi-2201) to understand the effects of dimensionality reduction on superconductivity. The researchers found an approximately 10% reduction in the optimal superconducting transition temperature. The study explores the tunability of the material through controlled oxygenation. | GHK-Cu | PubMed | 2026 |
| Not reported in abstract. | GHK-Cu | PubMed | 2026 |
| A fluorescent aptamer sensor based on a copper-based metal-organic framework was developed to monitor low-density lipoprotein (LDL) levels. The sensor demonstrated a linear range of 0.1-10,000 ng/mL and an ultra-low detection limit of 0.0789 ng/mL. It showed good accuracy and precision in human serum samples. | GHK-Cu | europepmc | 2026 |
| The study evaluated the structural and functional stability of Tachypleus gigas hemocyanin (TgH) across various temperatures and pH conditions. TgH retained 80% phenoloxidase activity up to 70 °C and demonstrated a melting temperature of 77.98 °C. The findings suggest potential applications in therapeutic and biotechnological fields. | GHK-Cu | europepmc | 2026 |
| Not reported in abstract. | GHK-Cu | PubMed | 2026 |
| This study aimed to develop and validate a nomogram based on the APRI-ALBI score for predicting graft failure in pediatric liver transplant recipients. A total of 289 children who underwent primary liver transplantation were analyzed. The nomogram achieved an AUC of 0.706 for graft failure prediction. | TB-500 (Thymosin Beta-4 Fragment) | europepmc | 2026 |